A trial testing different combinations of Nivolumab, Ipilimumab, and OX40 (CD134) agonist in advanced solid tumors, mainly NSCLC and bladder cancers, [100] did not show improved results as compared to Nivolumab combined to Ipilimumab. The gene discussed is TNFRSF4; the disease is non-small cell lung carcinoma.